Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2018;19(10):869-870.
doi: 10.1080/15384047.2018.1449618. Epub 2018 May 14.

Molecular drivers of metastatic castrate-resistant prostate cancer: New roads to resistance

Phoebe A Huang  1 , Douglas K Price  1 , William D Figg  1
Affiliations
Comment

Molecular drivers of metastatic castrate-resistant prostate cancer: New roads to resistance

Phoebe A Huang et al. Cancer Biol Ther. 2018.

Abstract

Numerous growth-inducing signaling pathways have been implicated in the development of metastatic castrate-resistant prostate cancer, but their cross-talk with androgen receptor functions remains poorly understood. A recent study published in Science Signaling by Chen et al. 1 has identified a novel androgen-mediated signaling axis driven by loss of SPDEF and gain of TGFBI to facilitate metastasis, which may explain the acquisition of resistance to androgen deprivation therapy. These findings suggest that therapeutic inhibition of androgen signaling may inadvertently promote castrate resistance by inhibiting tumor suppressive functions of the androgen receptor.

Keywords: ADT resistance; Androgen receptor; SPDEF; TGFBI; epithelial-mesenchymal transition; mCRPC; receptor signaling; tumor suppressor.

PubMed Disclaimer

Comment on

References

    1. Chen WY, Tsai YC, Yeh HL, Suau F, Jiang KC, Shao AN, Huang J, Liu YN. Loss of SPDEF and gain of TGFBI activity after androgen deprivation therapy promote EMT and bone metastasis of prostate cancer. Sci Signal. 2017;10. doi: 10.1126/scisignal.aam6826. - DOI - PubMed
    1. Coutinho I, Day TK, Tilley WD, Selth LA. Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence. Endocr Relat Cancer. 2016;23:T179–T97. doi: 10.1530/ERC-16-0422. PMID:27799360. - DOI - PubMed
    1. Zhu ML, Kyprianou N. Role of androgens and the androgen receptor in epithelial-mesenchymal transition and invasion of prostate cancer cells. FASEB J. 2010;24:769–77. doi: 10.1096/fj.09-136994. PMID:19901020. - DOI - PMC - PubMed
    1. Boudadi K, Antonarakis ES. Resistance to novel antiandrogen therapies in metastatic castration-resistant prostate cancer. Clin Med Insights Oncol. 2016;10:1–9. PMID:27013902 - PMC - PubMed
    1. Edwards J, Krishna NS, Grigor KM, Bartlett JM. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer. 2003;89:552–6. doi: 10.1038/sj.bjc.6601127. PMID:12888829. - DOI - PMC - PubMed

Publication types

LinkOut - more resources